Patrick F. Williams
Known title: Chief Financial OfficerCIK: 0001562229
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
STAAR Surgical Names New VP, Faces High Valuation Questions. STAAR Surgical appointed Andrew Pilon as Vice President of Business Development. Recent articles discuss whether the stock is undervalued or risky, noting its high trailing P/E of 283.5. The stock is currently trading near a key support level, with analyst targets ranging from $19.00 to $37.00.
Transaction History
| NPCE | ▼ Sell | Tax Withholding | 1,162 | $17K | 9/20/2026 | View on chart |
| NPCE | ▲ Buy | Grant | 16,820 | $0 | 5/15/2026 | View on chart |
| NPCE | ▲ Buy | Grant | 51,850 | $0 | 6/20/2025 | View on chart |
| STAA | ▲ Buy | Option Exercise | 8,153 | $0 | 3/12/2025 | View on chart |
| STAA | ▲ Buy | Option Exercise | 4,061 | $0 | 3/10/2025 | View on chart |
| STAA | ▲ Buy | Option Exercise | 2,614 | $0 | 3/7/2025 | View on chart |
| STAA | ▲ Buy | Option Exercise | 3,075 | $0 | 3/7/2025 | View on chart |
| STAA | ▲ Buy | Option Exercise | 2,614 | $0 | 3/7/2024 | View on chart |
| STAA | ▲ Buy | Option Exercise | 5,122 | $0 | 8/10/2023 | View on chart |
| STAA | ▼ Sell | Tax Withholding | 2,539 | $112K | 8/10/2023 | View on chart |
| STAA | ▲ Buy | Option Exercise | 5,121 | $0 | 6/6/2023 | View on chart |
| STAA | ▼ Sell | Tax Withholding | 1,987 | $109K | 6/6/2023 | View on chart |
| STAA | ▼ Sell | Tax Withholding | 289 | $16K | 3/10/2023 | View on chart |
| STAA | ▲ Buy | Option Exercise | 12,184 | $0 | 3/10/2023 | View on chart |
| STAA | ▼ Sell | Tax Withholding | 1,063 | $62K | 3/7/2023 | View on chart |
| STAA | ▲ Buy | Option Exercise | 1,711 | $99K | 3/7/2023 | View on chart |
| STAA | ▲ Buy | Option Exercise | 5,121 | $0 | 6/7/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 9,225 | $0 | 3/7/2022 | View on chart |
| STAA | ▼ Sell | Open Market | 5,121 | $714K | 9/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating
Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.
Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating. Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.